Chengdu Yinhe Biomedicine

Chengdu Yinhe Biomedicine Co., Ltd. is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of advanced cell therapies for cancer. As a key R&D subsidiary of the publicly listed Yinhe Biopharmaceutical Co., Ltd. (000806.SZ), the company focuses on next-generation Chimeric Antigen Receptor T-cell (CAR-T) technologies. Its lead candidate, MBC19 (iPD1 CD19 eCAR-T), is an autologous CAR-T therapy targeting CD19 with intrinsic PD-1 inhibition, currently undergoing Phase 2 clinical trials for B-cell lymphomas. The company leverages strategic partnerships with Sichuan University's State Key Laboratory of Biotherapy and Beijing Mali Biotechnology to advance its pipeline of immunotherapy products.